Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Titel:
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Auteur:
Schneeweiss, Andreas Michel, Laura L. Möbus, Volker Tesch, Hans Klare, Peter Hahnen, Eric Denkert, Carsten Kast, Karin Pohl-Rescigno, Esther Hanusch, Claus Link, Theresa Untch, Michael Jackisch, Christian Blohmer, Jens-Uwe Fasching, Peter A. Solbach, Christine Schmutzler, Rita K. Huober, Jens Rhiem, Kerstin Nekljudova, Valentina Lübbe, Kristina Loibl, Sibylle